JAC Advance Access published online on April 29, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh213
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 National Public Health
Institute, P.O. Box 310, FIN-90101 Oulu;
* To whom correspondence should be addressed. E-mail: liisa.tormakangas{at}ktl.fi.
Objectives: The efficacy of telithromycin,
a new ketolide antibiotic, was investigated in the treatment of
acute Chlamydia pneumoniae infection in a mouse
model. Methods: C57BL/6J mice were inoculated intranasally,
and the effects of three different doses of telithromycin (25, 50
and 100 mg/kg) were assessed after 5 and 10 days of treatment. Lungs
for culture, PCR, histopathology, and blood for serum samples were
collected immediately after each treatment period and at
3 weeks post-inoculation. C. pneumoniae-specific
antibodies were analysed, and the effect of treatment was assessed
by culture, detection of C. pneumoniae DNA and
determination of histopathological inflammatory changes in mouse
lungs. Results: Culture negativity in the lungs was
achieved with the higher doses, 50 and 100 mg/kg, after 10 days of
treatment. C. pneumoniae DNA was not totally eradicated
with the treatments, but the groups treated with 50 and 100 mg/kg
doses for 10 days had the lowest DNA positivity rates (10%)
3 weeks after the inoculation. In lung histopathology, the efficacy
of telithromycin on inflammatory changes was also dose-dependent: higher
doses were more effective in reducing the inflammatory reaction.
Overall, the 25 mg/kg dose had a weaker effect compared with the
others. Conclusions: Telithromycin had both time- and
dose-dependent effects on the eradication of chlamydia and on reducing
infection-induced inflammatory changes in mouse lungs.
Revised February 17, 2004
Accepted February 27, 2004
Original article
Treatment of acute Chlamydia pneumoniae infection
with
telithromycin in C57BL/6J mice
2 Department of Internal Services, National Public Health
Institute, Helsinki;
3 Clinical Pharmacology Anti-infectives,
Aventis Pharma, Paris, France
4 Department
of Medical Microbiology, University of Oulu, Oulu, Finland;
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. de Kruif, E. C.M. van Gorp, T. T. Keller, J. M. Ossewaarde, and H. ten Cate Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research Cardiovasc Res, February 1, 2005; 65(2): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|